Pricing Log in Create free account
Saturday 17 October 2026 Export STTK’s income statement to Excel — free account

Shattuck Labs, Inc.

STTK Healthcare Biotechnology

In the quarter to June 2026, revenue fell 10.3%, EPS grew 50.0% and free cash flow grew 1.01%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

5.42 0.11 −1.99%
Market cap
$555.0M
P/E
0.0×
Fwd P/E
−10.3×
Dividend yield
—
F-score
4/9
Altman Z
10.16
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.25
Total sells 0.59
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — 1 — — — —
Sell — — — — — — 2 2 1 — — —
Insider Ownership 33.56%

Capital & Financial Ratios $m

Market Cap 555.01
Revenue 5.61
Net Income (52.57)
Free Cash Flow (41.24)
Net Debt (208.30)
Current Ratio 27.59 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (10.30) (negative: loss-making)
P/S ratio 125.47 (above 10: high)
P/B ratio 3.33
Past 5Y EPS Growth —
This Y EPS Growth 30.68% (at or above 15%: strong)
Next Y EPS Growth (6.83%) (below 0%: weak)
Next Y revenue growth (88.89%) (below 0%: weak)
Next 5Y EPS Growth 5.95%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 88.3×, against a ten-year median of 11.7×; over the ten years it ranged from −61.3× in 2023 to 501× in 2021.
P/S against its own 10 years 67.79%
10-year low 10-year high
P/B against its own 10 years 79.45%
10-year low 10-year high
EV/Sales against its own 10 years 54.47%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 131 73 78 208
Receivables — — — —
Inventory — — — —
Other — — — —
143 79 82 213
2023 2024 2025 Q'26
Payables 2 2 2 4
ST’ Debt — — — —
Other — — — —
11 9 7 8

Compound Annual Growth %

10y 5y 3y
Sales — (36.82%) 15.32%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (23.27%) (22.38%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — 1 — 1
’24 1 2 3 0 6
’23 0 0 1 1 2
’22 — 0 0 0 1
’21 2 (4) 2 30 30
’20 3 3 2 1 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (10) — — —
’25 (12) (10) (9) (8) (40)
’24 (16) (11) (16) (17) (61)
’23 (26) (19) (17) (19) (81)
’22 (26) (16) (28) (24) (94)
’21 (11) (14) (13) (19) (57)
’20 (10) 2 (11) (14) (34)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (10) — — —
’25 (12) (10) (9) (8) (40)
’24 (16) (11) (16) (17) (61)
’23 (27) (19) (17) (19) (82)
’22 (29) (24) (29) (24) (106)
’21 (14) (17) (14) (21) (65)
’20 (11) 2 (11) (14) (34)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.13) (0.12) — — —
’25 (0.27) (0.24) (0.14) (0.12) (0.70)
’24 (0.37) (0.42) (0.33) (0.37) (1.49)
’23 (0.49) (0.50) (0.65) (0.41) (2.05)
’22 (0.58) (0.65) (0.58) (0.60) (2.41)
’21 (0.28) (0.56) (0.41) 0.18 (1.07)
’20 (0.86) (0.81) (1.54) (0.31) (2.36)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 17.51 7.88 1.85 1.33 0.94 0.69

Analyst estimates 2026–2028

Powerpack
High — — — — 60.52 59.57 9.46 7.77 11.76 3.70
People
People Employees — — — — 59 85 105 75 44 40
Revenue/emp, $m — — 0.00 0.00 0.17 0.35 0.01 0.02 0.13 0.03
Income, $m
Income, $m Revenue — — 22 10 10 30 1 2 6 1
Gross margin, % — — 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT — — (7) (24) (37) (45) (102) (87) (75) (49)
EBT margin, % — — (32.92) (242.56) (368.46) (149.83) (15,635.74) (5,268.44) (1,318.13) (4,880.90)
Net income — 0 (7) (24) (37) (45) (102) (87) (75) (49)
Depreciation — — 0 0 1 4 4 3 2 3
Per share, $
Per share, $ Revenue — — 0.54 1.31 0.64 0.71 0.02 0.04 0.11 0.01
Earnings — — (0.18) (3.17) (2.36) (1.07) (2.41) (2.05) (1.49) (0.70)
Cash flow — — (0.17) (2.78) (2.17) (1.36) (2.23) (1.91) (1.19) (0.57)
Capex — — 0.00 (0.06) (0.05) (0.19) (0.27) (0.01) 0.00 0.00
Free cash flow — — (0.17) (2.84) (2.22) (1.55) (2.50) (1.92) (1.19) (0.57)
Book value — — 0.91 1.92 19.98 6.47 4.16 3.40 1.57 1.18
Shares, m — — 42 8 16 42 42 43 51 70
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — 14.36 14.36 81.81 11.92 3.45 194.36 10.74 45.31
P/B — — 0.00 0.00 2.62 1.32 0.60 2.23 0.77 3.08
EV/Sales — — 1.35 1.35 48.04 2.96 (1.80) 115.53 (2.02) 31.38
EV/FCF — — (0.51) (0.51) (13.88) (1.37) 0.52 (2.34) 0.19 (4.40)
Cash, $m
Cash, $m Operating cash flow — — (7) (21) (34) (57) (94) (81) (61) (40)
Capex — — (1) 0 (1) (8) (12) 0 0 0
Free cash flow — — (7) (21) (34) (65) (106) (82) (61) (40)
Balance, $m
Balance, $m Working capital — — 45 22 329 264 160 132 70 75
Total debt — — — — — — 5 — — —
Net debt — — (60) (39) (335) (269) (161) (131) (73) (78)
Shareholders’ equity — — 38 15 310 272 176 145 80 82
Returns, %
Returns, % ROA — — (21.68) (42.40) (18.58) (13.89) (40.46) (47.85) (60.18) (53.61)
ROIC — — 0.00 0.00 0.00 (948.80) (434.10) (408.19) (758.46) (744.34)
ROE — — 32.38 105.12 (26.59) (15.46) (45.52) (54.41) (67.23) (60.25)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2025

Charts ten years each

Shattuck Labs, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SLN Silence Therapeutics PLC Sponsored ADR $581.1M — (loss-making) — (loss-making) +197.18% (above 0%: growing) n/m +106.95% (above 0%: growing) 97.39% 0.00% Compare
SGMT Sagimet Biosciences Inc. $574.7M — (loss-making) — (loss-making) — n/m −21.95% (below 0%: shrinking) 100.00% 0.00% Compare
DBVT DBV Technologies S.A. $572.6M — (loss-making) — −53.33% (below 0%: shrinking) n/m −56.15% (below 0%: shrinking) 100.00% (7,228.57%) Compare
VALN Valneva SE Sponsored ADR $560.4M 59.7× 19.4× −17.29% (below 0%: shrinking) n/m −56.05% (below 0%: shrinking) 15.29% (76.67%) Compare
STTK Shattuck Labs, Inc. $555.0M — (loss-making) — (loss-making) −10.31% (below 0%: shrinking) n/m +1.01% (above 0%: growing) 100.00% 0.00%
VECT VectivBio Holding AG $545.5M — (loss-making) — (loss-making) — n/m — 91.93% 0.00% Compare
PBYI Puma Biotechnology, Inc. $543.0M 18.2× 24.2× +7.75% (above 0%: growing) +33.33% (above 0%: growing) −88.45% (below 0%: shrinking) 77.92% 13.42% Compare
DRUG Bright Minds Biosciences Inc. $534.7M — (loss-making) — — n/m −124.63% (below 0%: shrinking) 0.00% 0.00% Compare
FTH Faeth Therapeutics, Inc. $532.3M — (loss-making) — — n/m −174.24% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $552.9M — — −4.77% — −56.15% 84.93% 0.00%

All 614 Biotechnology stocks →

Shattuck Labs, Inc. (STTK) key facts

  • Shattuck Labs, Inc. (STTK) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, STTK traded at $5.42, a market capitalization of $555.0 million.
  • Return on equity was −60.3% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 10.16 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Shattuck Labs, Inc. (STTK) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/STTK · Data as of Sep 30, 2025 · For information only; not investment advice. · © 2026 stockrow.com